Novartis to Buy UK Biotech Myricx for Up to $1.5 Billion, Boosting ADC Portfolio
Novartis is significantly expanding its oncology portfolio after securing an antibody-drug conjugate technology designed to deliver potent anticancer...
Search results for "ADC"
Qurient’s Mocaciclib Opens New Combination Frontiers for Hard-to-Treat Breast Cancer
Qurient announced on June 29 that it presented key clinical data highlighting the mechanistic advantages of its CDK7-inhibiting oncology candidate,...
ABL Bio to Present Two Bispecific Antibody ADC Posters at AACR
ABL Bio announced on the 19th that it will participate in this year’s American Association for Cancer Research Annual...
Alteogen to Present Subcutaneous ADC Formulation Research at International Forum in June
Alteogen announced on the 23rd that it will present research results regarding subcutaneous dosing for antibody-drug...
FDA Approves Clinical Trial for Abl Bio’s Dual-Antibody ADC Candidate
Abl Bio announced on March 3rd that the U.S. Food and Drug Administration has approved the Investigational New Drug...
A Ray of Hope: ‘Low Expression’ Changes the Landscape of Breast Cancer Treatment
The treatment landscape for metastatic breast cancer is undergoing a significant shift.
Can We Break Through Chemotherapy Resistance? A New Target for Triple-Negative Breast Cancer Appears
Among breast cancers, ‘triple-negative breast cancer ’ is particularly challenging to treat.
Ligakem Bio Receives ADC Platform Technology Fees from Ono Pharmaceutical
Ligakem Bioscience announced on the 8th that it is set to receive milestone payments related to the development...
Novartis Halts Lu-NeoB Development After Early Clinical Data Fall Short
Novartis has discontinued the development of Lu-NeoB, an experimental cancer therapy designed to seek out tumor cells...
Samsung Biologics Bets 2.7 Trillion Won on Peptides in South Korea’s Largest Biotech M&A Deal
Samsung Biologics is making a major push into peptide-based medicines—widely used in weight-loss and diabetes...